Link between lipoprotein-associated phospholipase A2 gene expression of peripheral-blood mononuclear cells and prognostic outcome after acute ischemic stroke.

AIM To evaluate the potential of the lipoprotein-associated phospholipase A(2) (Lp-PLA(2) level as a biomarker in the prediction of prognostic outcome in patients with acute ischemic stroke (IS). METHODS From October 2008 to March 2010, 130 patients with acute IS were prospectively enrolled in the study and their medical records were reviewed. A blood sample was collected from each patient 48 hours after acute IS, as well as from 20 healthy volunteers as controls. Messenger-RNA (mRNA) expression of Lp-PLA(2) of peripheral-blood mononuclear cells (PBMNCs) relative to that of β actin was measured using quantitative reverse transcription polymerase chain reaction (RT-PCR). RESULTS Patients with acute IS exhibited significantly higher Lp-PLA(2) mRNA expression of PBMNCs than the control group (p <0.0001). Lp-PLA(2) mRNA expression of PBMNCs in patients with a major adverse clinical outcome (MACO) (defined as recurrent stroke or death) within 90 days was significantly higher than in patients without MACO (p=0.006). Furthermore, elevated Lp-PLA(2) mRNA expression was strongly associated with old age, diabetes mellitus, a positive history of significant coronary arterial disease and significant stenosis of the extra-cranial carotid arteries (all p <0.04), and positively correlated with the body mass index, leukocyte count, and serum levels of total cholesterol and low-density lipoprotein cholesterol. Multivariate analysis revealed that Lp-PLA(2) mRNA expression of PBMNCs was a significant independent predictor of MACO within 90 days (p= 0.011). CONCLUSION Elevated Lp-PLA(2) mRNA expression of PBMNCs seems to be a potential biomarker for predicting an unfavorable outcome in patients with acute IS.

[1]  ZiadMallat,et al.  Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease , 2010 .

[2]  A. Kastrati,et al.  Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  S. Kasner,et al.  Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Risk-Stratification of Patients With TIA , 2009, Stroke.

[4]  D. Stafforini,et al.  The emerging roles of PAF acetylhydrolase This work was supported by National Institutes of Health Grants HL44513, HL35828, and HL087018. Published, JLR Papers in Press, October 6, 2008. , 2009, Journal of Lipid Research.

[5]  Qingbo Xu,et al.  Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. , 2008, European heart journal.

[6]  R. Sacco,et al.  Lipoprotein-Associated Phospholipase A2 Activity and Risk of Recurrent Stroke , 2008, Cerebrovascular Diseases.

[7]  F. Meyer,et al.  Enhanced Expression of Lp-PLA2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques , 2008, Stroke.

[8]  C. Furberg,et al.  Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. , 2008, Journal of the American College of Cardiology.

[9]  S. Solomon,et al.  Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[10]  N. Hagiwara,et al.  Serum creatinine on admission predicts long-term mortality in acute myocardial infarction patients undergoing successful primary angioplasty: data from the Heart Institute of Japan Acute Myocardial Infarction (HIJAMI) Registry. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[11]  G. Berglund,et al.  Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[12]  A. Youssef,et al.  Level and value of interleukin-18 in patients with acute myocardial infarction undergoing primary coronary angioplasty. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[13]  G. Berglund,et al.  The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. , 2007, Atherosclerosis.

[14]  R. Sacco,et al.  High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. , 2006, Archives of internal medicine.

[15]  M. Elisaf,et al.  Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. , 2005, Clinical chemistry.

[16]  R. Sacco,et al.  Relative elevation in baseline leukocyte count predicts first cerebral infarction , 2005, Neurology.

[17]  M. Hersberger,et al.  Inflammatory Markers at the Site of Ruptured Plaque in Acute Myocardial Infarction: Locally Increased Interleukin-6 and Serum Amyloid A but Decreased C-Reactive Protein , 2005, Circulation.

[18]  H. Yip,et al.  Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. , 2004, Chest.

[19]  J. J. Griffin,et al.  Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction , 2003, Circulation.

[20]  C. Ruiz,et al.  High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. , 2003, Journal of vascular surgery.

[21]  C. Packard,et al.  Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease , 2003, Current opinion in lipidology.

[22]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[23]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[24]  R. Virmani,et al.  Elevated C-Reactive Protein Values and Atherosclerosis in Sudden Coronary Death: Association With Different Pathologies , 2002, Circulation.

[25]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[26]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[27]  Yasuo Ikeda,et al.  Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. , 1999, Biochemical and biophysical research communications.

[28]  D. Tew,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.

[29]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[30]  G. Zimmerman,et al.  Human macrophages secret platelet-activating factor acetylhydrolase. , 1990, The Journal of biological chemistry.

[31]  Z. El-Sayed.  McIntyre TM, Prescott SM, Stafforini DM. The emerging roles of PAF acetylhydrolase. Lipid Res 2009; 50 Suppl: S255-9. , 2012 .

[32]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[33]  R. Sacco,et al.  High-Sensitivity C-Reactive Protein , Lipoprotein-Associated Phospholipase A 2 , and Outcome After Ischemic Stroke , 2006 .

[34]  M. H.,et al.  LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 AS AN INDEPENDENT PREDICTOR OF CORONARY HEART DISEASE , 2000 .

[35]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[36]  R. Stout.  Ageing and atherosclerosis. , 1987, Age and ageing.